10-Q: Centene Q3 2025: $6.6B Loss on Goodwill Impairment, Revenue Up

Centene Corporation reported a significant net loss of $6.6 billion in Q3 2025, primarily due to a $6.7 billion goodwill impairment, despite an 18% increase in total revenues.

Summary

• GAAP net loss attributable to Centene was $(6,631) million for the three months ended September 30, 2025, compared to net earnings of $713 million for the same period in 2024.
• A non-cash goodwill impairment charge of $6,723 million was recorded in the third quarter of 2025, along with a $22 million real estate impairment.
• Total revenues increased 18% year-over-year to $49.7 billion for Q3 2025, and 19% to $145.1 billion for the nine months ended September 30, 2025.
• Premium and service revenues grew 22% year-over-year to $44.9 billion for Q3 2025.
• Adjusted diluted earnings per share (EPS) was $0.50 for Q3 2025, a decrease from $1.62 in Q3 2024.
• The Health Benefits Ratio (HBR) increased to 92.7% in Q3 2025 from 89.2% in Q3 2024, driven by higher Marketplace medical costs, lower estimated risk adjustment revenue, and changes from the Inflation Reduction Act (IRA) in the Prescription Drug Plan (PDP) business.
• The Selling, General & Administrative (SG&A) expense ratio improved to 7.0% in Q3 2025 from 8.3% in Q3 2024.
• Managed care membership decreased by 672 thousand members, or 2%, year-over-year to 28.0 million.
• Operating cash flows provided $1.4 billion in Q3 2025 and $4.7 billion for the nine months ended September 30, 2025.
• Medicaid membership declined primarily due to redeterminations, while Marketplace membership increased 29% and Medicare PDP membership increased 18% year-over-year.
• The One Big Beautiful Bill Act (OBBBA), passed in July 2025, is expected to have various implications, including potential membership impacts to Medicaid and the non-renewal of Marketplace enhanced Advance Premium Tax Credits (APTCs).

Sentiment

Score: 3

Explanation: The significant goodwill impairment leading to a substantial net loss, coupled with a worsening Health Benefits Ratio and declining adjusted EPS, indicates fundamental operational challenges and a deterioration in asset quality. While revenue growth is present, it is overshadowed by increased medical costs and regulatory headwinds impacting profitability. The ongoing legal proceedings add further uncertainty and potential financial risk. The increase in the debt-to-capital ratio also signals increased leverage. These factors contribute to a largely negative sentiment.

Positives

• Total revenues increased 18% in Q3 2025 and 19% for the nine months ended September 30, 2025, demonstrating strong top-line growth.
• Premium and service revenues grew 22% in Q3 2025, indicating robust core business expansion.
• The SG&A expense ratio improved to 7.0% in Q3 2025 from 8.3% in Q3 2024, reflecting expense leveraging over higher revenues.
• Operating cash flows were strong, providing $1.4 billion in Q3 2025 and $4.7 billion for the nine months ended September 30, 2025.
• Marketplace membership increased 29% year-over-year due to expanded geographic footprint and strong open enrollment results.
• Medicare Prescription Drug Plan (PDP) membership increased 18% year-over-year.
• Medicare Advantage Star Ratings improved, with approximately 60% of membership enrolled in plans rated 3.5 stars or higher (up from 55% in the prior year), including 20% in 4-star rated plans (up from 1% in the prior year).
• Secured several contract renewals and new contracts in the Medicaid segment across multiple states, including Iowa, Mississippi, Florida, Kansas, Michigan, Texas, New Hampshire, Oklahoma, Nebraska, and California.

Negatives

• Reported a GAAP net loss of $(6,631) million in Q3 2025 and $(5,573) million for the nine months ended September 30, 2025, primarily due to a $6.7 billion goodwill impairment.
• Adjusted diluted EPS decreased significantly to $0.50 in Q3 2025 from $1.62 in Q3 2024.
• The Health Benefits Ratio (HBR) worsened to 92.7% in Q3 2025 from 89.2% in Q3 2024, indicating increased medical costs relative to premiums.
• Managed care membership decreased by 672 thousand members (2%) year-over-year.
• Medicaid membership declined due to redeterminations and the impact of the One Big Beautiful Bill Act (OBBBA).
• Medicare Advantage membership declined 10% year-over-year.
• Commercial segment gross margin decreased by $620 million in Q3 2025 due to increased Marketplace medical costs and lower estimated risk adjustment revenue.
• Medicaid segment gross margin decreased by $799 million for the nine months ended September 30, 2025, driven by higher medical costs, particularly in behavioral health, home health, and high-cost drugs.
• Investment and other income decreased by $237 million for the nine months ended September 30, 2025, due to lower interest rates, lower average investment balances, and the absence of net gains on divestitures seen in the prior year.
• The debt-to-capital ratio increased to 45.5% at September 30, 2025, from 41.2% at December 31, 2024, primarily due to the goodwill impairment reducing total stockholders' equity.
• Ongoing bid protests in Pennsylvania, Arizona, Georgia, and Texas could negatively impact future results of operations.

Risks

• Ability to design and price products that are competitive and/or actuarially sound.
• Ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs.
• Rate cuts, insufficient rate changes, or other payment reductions or delays by government payors affecting government businesses.
• The effect of social, economic, and political conditions, geopolitical events, and state and federal policies, including funding for government-sponsored healthcare programs.
• Changes in federal or state laws or regulations, including those related to the ACA, enhanced Advance Premium Tax Credits (APTCs), and program integrity initiatives.
• Unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation, and tariffs.
• Ability to maintain or achieve improvement in Centers for Medicare and Medicaid Services (CMS) Star ratings and other quality scores.
• Competition for providers, broker distribution networks, contract reprocurements, and organic growth.
• Ability to comply with contract terms and state and federal regulations, and effectively oversee third-party vendors.
• Disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in third-party vendor relationships.
• Impairments to real estate, investments, goodwill, and intangible assets, as evidenced by the $6.7 billion goodwill impairment in Q3 2025.
• Changes in senior management, loss of key personnel, or inability to attract, hire, integrate, and retain skilled personnel.
• Membership and revenue declines or unexpected trends, such as Medicaid redeterminations.
• Changes in healthcare practices, new technologies, and advances in medicine.
• Ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws.
• Changes in macroeconomic conditions, including inflation, interest rates, and volatility in financial markets.
• Negative public perception of the Company and the managed care industry.
• Uncertainty concerning government shutdowns, debt ceilings, or funding.
• Tax matters.
• Disasters, climate-related incidents, acts of war or aggression, or major epidemics.
• Changes in expected contract start dates and terms, and delays in regulatory approval of contracts due to protests.
• The expiration, suspension, or termination of contracts with federal or state governments.
• Difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings, or matters, including the federal securities class action and derivative lawsuits.
• Challenges to contract awards, such as ongoing bid protests in Pennsylvania, Arizona, Georgia, and Texas.
• Cyber-attacks or other data security incidents or failure to comply with applicable privacy, data, or security laws and regulations.
• Restrictions and limitations in connection with indebtedness, and potential downgrade of credit ratings.
• The One Big Beautiful Bill Act (OBBBA) may reduce Medicaid Expansion eligibility, require more frequent redeterminations, add cost-sharing, and potentially reduce federal funding for Medicaid, increasing morbidity and changing program design.
• The OBBBA includes a restriction against paying certain 'prohibited entities' as of October 1, 2025, which could create access to care issues and network gaps.
• The expiration of enhanced APTCs at the end of 2025, the Marketplace Integrity & Affordability Final Rule, and the OBBBA's additional restrictions on APTCs are anticipated to reduce 2026 Marketplace membership and increase population morbidity.
• The Inflation Reduction Act (IRA) significantly changed Medicare Part D, resulting in a meaningful shift in cost-sharing responsibilities and a significant increase in premiums for Prescription Drug Plans (PDPs).
• Potential delays in payments from CMS for Part D risk-sharing programs could materially adversely affect cash flows.

Future Outlook

The company expects to implement corrective pricing actions for 2026 in states representing approximately 95% of its Marketplace membership to address higher projected morbidity. The combined impact of the expiration of enhanced Advance Premium Tax Credits (APTCs), the Marketplace Integrity & Affordability Final Rule, and the One Big Beautiful Bill Act (OBBBA) is anticipated to reduce 2026 Marketplace membership and increase the overall morbidity of the Marketplace population. Medicaid membership is expected to see further reductions due to ongoing state redetermination processes and OBBBA requirements, which could also increase morbidity in the Medicaid Expansion population starting in 2027 and potentially reduce federal funding for Medicaid from 2028. The OBBBA's restriction on payments to 'prohibited entities' starting October 1, 2025, may create access to care issues. Changes from the Inflation Reduction Act (IRA) in Medicare Part D have led to a significant increase in premiums for Prescription Drug Plans (PDPs). Dual-eligible beneficiaries will be required to receive integrated care through aligned Medicaid and Medicare Advantage D-SNPs starting in 2030 (or 2027 for new enrollees). For the remainder of 2025, the company expects net dividends of approximately $200 million from insurance subsidiaries and an additional $200 million in capital expenditures. The company believes its current liquidity and capital resources will be sufficient for at least 12 months, but may consider increasing borrowings or raising additional funds through debt or equity, or pursuing refinancing opportunities.

Management Comments

• "We remain focused on our promise of delivering high-quality healthcare services on behalf of states and the federal government to under-insured and uninsured families and commercial organizations."
• "Our decades of experience and deep industry knowledge have allowed us to deliver cost-effective services to our government partners and our members."
• "With a focus on the personalization of healthcare technology, we continue the use of data and analytics to improve the provider and member experience."
• "We continue to believe we have both the capacity and capability to successfully navigate industry changes to the benefit of our members, customers, providers, and shareholders."

Industry Context

The healthcare industry is currently experiencing an accelerated increase in medical cost trends, driven by rising medical demand, expanded access to care (e.g., behavioral healthcare, home and community-based services), and the rapid introduction of new, high-cost pharmaceuticals. Significant legislative changes, such as the passage of the One Big Beautiful Bill Act (OBBBA) and the impending expiration of enhanced Advance Premium Tax Credits (APTCs), are creating considerable uncertainty for consumers regarding the future availability, affordability, and access to health insurance. These changes may be prompting members to seek care at an increased rate due to potential eligibility and subsidy shifts. The Inflation Reduction Act (IRA) has also profoundly reshaped Medicare Part D, leading to a substantial reallocation of cost-sharing responsibilities and a notable increase in premiums for Prescription Drug Plans (PDPs). Furthermore, CMS policies are pushing for greater integration of care for dual-eligible beneficiaries, mandating aligned Medicaid and Medicare Advantage Dual Eligible Special Needs Plans (D-SNPs) from 2027/2030.

Comparison to Industry Standards

• The company's Medicare Advantage Star Ratings improved, with approximately 60% of its Medicare Advantage membership enrolled in plans rated 3.5 stars or higher in 2026 (up from 55% in the prior year), including approximately 20% in 4-star rated plans (up from 1% in the prior year). This indicates an improvement in quality performance relative to its own historical benchmarks, which is a key metric in the Medicare Advantage industry.

Corporate Governance

Legal Proceedings

• A putative federal securities class action, Brock Lunstrum v. Centene Corp., et al., was filed on July 9, 2025, alleging that the Company made false and misleading statements regarding its 2025 earnings guidance in violation of federal securities laws.
• Four related derivative lawsuits (Franchi v. London, et al., Keippel v. London, et al., Shipon v. London, et al., and Nante v. London, et al.) were filed between July 31, 2025, and September 30, 2025, against the Company (as nominal defendant), members of the board of directors, and certain officers, alleging breach of fiduciary duties and other misconduct in connection with the statements at issue in the Securities Action.
• The Company denies any wrongdoing and is vigorously defending itself against these claims.
• An adverse outcome in any of these legal matters could potentially have a materially adverse impact on the Company's financial position, results of operations, cash flow, or liquidity.

Stakeholder Impact

• Shareholders: Experienced a significant GAAP net loss and goodwill impairment, negatively impacting shareholder equity and diluted EPS. The decline in adjusted EPS and ongoing legal proceedings pose further financial and reputational risks.
• Members: Regulatory changes, including the One Big Beautiful Bill Act (OBBBA), the expiration of enhanced Advance Premium Tax Credits (APTCs), and Inflation Reduction Act (IRA) changes to Medicare Part D, create uncertainty regarding future eligibility, affordability, and access to health insurance, potentially affecting coverage and out-of-pocket costs.
• Providers: The OBBBA's restriction against paying certain 'prohibited entities' as of October 1, 2025, has the potential to create access to care issues and network gaps.
• Government Partners: The company continues to work with state partners to establish appropriate Medicaid premium rates and analyze policy implications, indicating ongoing collaboration despite regulatory shifts and challenges.
• Creditors: The debt-to-capital ratio increased due to the goodwill impairment, which could be a concern for creditors, although the company remains in compliance with debt covenants and has available liquidity.

Next Steps

• Continue working with state partners to establish Medicaid premium rates that appropriately match the acuity of the population and reflect recent medical cost trends.
• Provide states with data to help them analyze the implications of policy decisions and design effective risk adjustment programs.
• Address medical cost trends through the implementation of new clinical initiatives, care management plans, thoughtful network design, and ongoing rigor to combat fraud, waste, and abuse.
• Advocate for legislation and regulations aimed at leveraging Medicaid and the Health Insurance Marketplace to maintain health insurance coverage and affordability for consumers.
• Navigate evolving regulations related to dual-eligible beneficiaries and integrated care models.
• Monitor and respond to ongoing bid protests in Pennsylvania, Arizona, Georgia, and Texas.
• Expect net dividends of approximately $200 million from insurance subsidiaries for the remainder of 2025.
• Expect to spend approximately $200 million in additional capital expenditures for the remainder of 2025.
• Potentially increase borrowings on the Revolving Credit Facility.
• Potentially raise additional funds for working capital and other purposes through debt or equity issuance, or the sale of investment securities.
• Strategically pursue refinancing or redemption opportunities to extend maturities and/or improve terms of indebtedness.

Key Dates

Recommendation

The significant GAAP net loss driven by a $6.7 billion goodwill impairment, coupled with a worsening Health Benefits Ratio and declining adjusted EPS, indicates fundamental operational challenges and a deterioration in asset quality. While revenue growth is present, it is overshadowed by increased medical costs and regulatory headwinds impacting profitability. The ongoing federal securities class action and derivative lawsuits add further uncertainty and potential financial risk. The increase in the debt-to-capital ratio also signals increased leverage. These factors suggest a negative outlook for the stock, warranting a 'sell' recommendation for a seasoned investor.

Keywords

Healthcare, Managed Care, Medicaid, Medicare, Marketplace, Health Insurance, 10-Q, Financial Results, Earnings, Goodwill Impairment, Revenue, Medical Costs, HBR, SG&A, Membership, Regulatory Changes, OBBBA, IRA, APTC, Risk Adjustment, Legal Proceedings, Stock Repurchase, Debt